Market Mirror Wire

How big is the Biosimilar Market in Europe? According to the latest report by IMARC Group, titled " Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 ," the biosimilar market in Europe size reached US$ 9,841 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 35,993 Million by 2028, exhibiting a growth rate (CAGR) of 20.41% during 2023-2028. Request for a PDF sample of this report:  https://www.imarcgroup.com/europe-biosimilar-market/requestsample What is Biosimilar? Biosimilars are medical products that are generally manufactured from biological substances, such as microorganisms and animal or plant cells. They are extensively used in the production of vaccines, therapeutic proteins and monoclonal antibodies. Additionally, they are utilized by healthcare professionals for preventing, determining, and treating numerous medical ailments. These products are usually produced under the guidance of licen...

IMARC Group has recently released a new research study titled " Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 ", offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios. The biosimilar market in Europe size reached US$ 9,841 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 35,993 Million by 2028, exhibiting a growth rate (CAGR) of 20.41% during 2023-2028. Biosimilars are medical products that are generally manufactured from biological substances, such as microorganisms and animal or plant cells. They are extensively used in the production of vaccines, therapeutic proteins and monoclonal antibodies. Additionally, they are utilized by healthcare professionals for preventing, determining, and treating numerous medical ailments. These products are usually produced under the guida...

According to the latest report by IMARC Group, titled " Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027 ," the  biosimilar market in Europe reached a value of US$ 6,735 Million  in 2021. Looking forward, IMARC Group expects the market to reach US$ 25,446 Million by 2027, exhibiting at a CAGR of 22.8% during 2022-2027. Biosimilars are biotherapeutic products that are identical copies of original prescription medicine manufactured by a different company. The drug is produced using living organisms and cells that have complex molecular structures and are manufactured after the patent of the reference product expires. The manufacturer then seeks approval from regulatory authorities to produce biosimilar product versions. Biosimilars are cheaper than their original counterparts and similar in efficacy, safety, and quality. In Europe, the biosimilars market is largely driven by rapid technological advancements and ...